Skip to main content
English version. Prefer Traditional Chinese? Switch to Chinese
Patient guide · Prescription Per TDA consensus · Updated 2026-05-04

Hidradenitis suppurativa (HS) — complete patient guide
Acne inversa, Hurley staging, the adalimumab era

Hidradenitis suppurativa (HS, also called acne inversa) is a chronic, relapsing inflammatory follicular disease occurring in friction-prone fold areas (axillae, groin, buttocks, submammary). Prevalence in Taiwan is ~0.3%, mean age of onset 23.2 years. Many patients are misdiagnosed as recurrent boils. This article covers Hurley staging, NHI-covered adalimumab + secukinumab regimens, and lifestyle modifications.

Note:HS early symptoms are often misdiagnosed as ordinary boils or folliculitis and treatment is delayed. If lesions recur at the same site, dermatologist evaluation is recommended.
Key Facts (TDA consensus)

HS is more than simple folliculitis. It is chronic inflammation → forming Subcutaneous tunnels (sinus tracts) → an auto-inflammatory disease with irreversible tissue destruction and scarring.The earlier the treatment, the better the outcome. In Asia, prevalence is higher in men than women (opposite of Europe/US).

What is Hidradenitis Suppurativa (HS)?

HS is a chronic inflammatory disease of follicular occlusion in apocrine-bearing areas (axilla, groin, perianal, inframammary, buttocks). Mistaken for "regular boils" or "abscesses," HS actually involves recurrent painful nodules → abscess → sinus tracts → scarring. Lifetime prevalence ~1%, F:M = 3:1, peaks 20-40 years old. Smoking and obesity strongly associated.

Diagnostic Criteria (3 hallmarks)

  1. Typical lesions: deep painful nodules, abscesses, sinus tracts, scarring
  2. Typical sites: axillae, groin, inframammary, perianal, buttocks (≥ 2 sites)
  3. Recurrent / chronic: ≥ 2 episodes within 6 months

Hurley Staging

StageFeaturesTreatment focus
Hurley ISingle / few nodules & abscesses; no sinus tracts or scarringTopical clindamycin, oral tetracycline, lifestyle
Hurley IIRecurrent abscesses with sinus tracts and scarring; widely separated lesionsOral antibiotics (combinations), biologics (Adalimumab / Secukinumab), surgical deroofing
Hurley IIIDiffuse involvement, multiple interconnected sinus tracts, extensive scarringBiologics + wide excision surgery

Treatment Ladder

Mild (Hurley I) / All stages baseline

  • Lifestyle: smoking cessation, weight loss (BMI < 30 strongly correlates with improvement), avoid mechanical friction (loose clothing), gentle washing
  • Topical clindamycin 1% solution BID for active lesions
  • Topical resorcinol 15%: dissolves keratin plugs, applied to active nodules
  • Antiseptic washes: chlorhexidine, benzoyl peroxide
  • Intralesional triamcinolone: 5-10 mg/mL for acute painful nodules — rapid relief

Moderate (Hurley II)

  • Oral antibiotics: tetracycline (doxycycline 100 mg BID × 3-6 mo) or clindamycin 300 mg BID + rifampin 300 mg BID × 10 weeks (gold standard combination)
  • Hormonal therapy: COCP (cyproterone-containing) or spironolactone 50-150 mg/d for women
  • Acitretin / isotretinoin: limited data; isotretinoin disappointing for HS specifically

Moderate-severe (Hurley II-III) — Biologics

DrugMechanismDosePhase-3 efficacy
Adalimumab (Humira)Anti-TNFα40 mg weekly (note: 2024 update; was bi-weekly previously)HiSCR50 wk 12: ~ 50% (PIONEER I/II); 41.8% vs 26.0% placebo
Secukinumab (Cosentyx)Anti-IL-17ASC 300 mg weekly × 5 → q2w or q4wHiSCR wk 16: 41.8-45.0% (SUNSHINE / SUNRISE 2023)
Bimekizumab (off-label / pipeline)Anti-IL-17A & FSC q4wHiSCR wk 16: ~ 50% (BE-HEARD)
Infliximab (off-label)Anti-TNFα IV5 mg/kg IV q8wOpen-label data supportive

Surgical options

  • Deroofing: removes the roof of sinus tracts and abscesses, leaves base for healing — preferred for limited disease
  • Wide local excision: removes all involved tissue with margins; for severe Hurley III, may require flap closure
  • CO₂ / Er:YAG laser: laser deroofing with reduced bleeding
  • Hair removal laser (Nd:YAG, Alexandrite, IPL): reduces follicular load, prevents new lesions

Comorbidities

  • Obesity, metabolic syndrome (HS is independently associated)
  • Cardiovascular disease (1.5-2× elevated)
  • Inflammatory bowel disease (Crohn's especially, 5-8% HS patients)
  • Spondyloarthritis
  • Depression / anxiety / suicide risk markedly elevated — QoL severely impacted
  • Squamous cell carcinoma in long-standing HS scars (rare but reported)

Summary

HS is often misdiagnosed as "boils" for years before correct identification. Average diagnostic delay is 7-10 years. Early recognition + lifestyle changes + appropriate medical / surgical approach can significantly improve outcomes. Biologics (Adalimumab, Secukinumab) have transformed moderate-to-severe HS treatment — patients who previously suffered through years of recurrent abscesses now achieve substantial control. If you have recurrent painful "boils" in 2+ apocrine areas, see a dermatologist for HS evaluation.